Mode
Text Size
Log in / Sign up
Phase 4 Completed N=32 Randomized Double-blind Treatment

Topiramate Treatment of Hazardous and Harmful Alcohol Use in Veterans With TBI

Traumatic Brain Injury (TBI) · Hazardous and Harmful Alcohol Use
Source: ClinicalTrials.gov NCT01750268 ↗
Enrolled (actual)
32
Serious AEs
12.5%
Results posted
Oct 2020
Primary outcomePrimary: Change in the Number of Drinking Days Per Week as Assessed by the Timeline Followback (TLFB) — 2.2; 1.6 Drinking Days per week

Summary

The goal of the proposed project is to improve the treatment of veterans with co-occurring traumatic brain injury (TBI) and hazardous or harmful alcohol use. The PI and coinvestigators will conduct a pilot controlled clinical trial of topiramate for the treatment of these co-occurring disorders.

Outcome Measures

OutcomeResultp-value
PRIMARY
Change in the Number of Drinking Days Per Week as Assessed by the Timeline Followback (TLFB)
2.2; 1.6
SECONDARY
Change in TBI Symptom Severity as Assessed by the Neurobehavioral Symptom Inventory (NSI)
16.3; 19.3

Eligibility Criteria

Inclusion Criteria

  • Male and female veterans.
  • Ages 18 to 65 (inclusive).
  • TBI: a history of mild traumatic brain injury, as defined by American Congress of Rehabilitation Medicine (ACRM) and VA, in the chronic, stable phase of recovery (>6 months from injury). The ACRM defines mild TBI as a traumatically-induced physiological disruption of brain function as demonstrated by at least one of the following:

3.a. loss of consciousness of up to 30 minutes;

3.b. any loss of memory for events immediately before or after the event;

3.c. any alteration in mental state at the time of the event, for example feeling dazed, disoriented, or confused; and

3.d. a focal neurological deficit or deficits that may or may not have been transient, for example loss of coordination, speech difficulties, or double vision. ACRM's definition further specifies that a person may be designated as having a mild TBI only if the severity of the injury does not include a loss of consciousness that lasted longer than 30 minutes, and post-traumatic amnesia lasting longer than 24 hours.

Rationale:

  • This is the most common description of patients currently served by our VA facilities.
  • Studies at this stable phase will facilitate detection of otherwise subtle changes as findings are less likely to be confounded by 'spontaneous' recovery.
  • Current (past month) hazardous alcohol use or harmful alcohol use.

4.a. Hazardous use is drinking that must meet criteria for "at-risk" or "heavy" drinking by National Institute on Alcohol Abuse and Alcoholism (NIAAA) criteria: Subjects must report current (past 30 day) "at-risk" or "heavy" drinking on an average weekly basis, consisting of an average of 15 or more standard drinks per week for men and 8 or more standard drinks per week for women during the 30 days prior to Screening Visit 1 as measured by the Alcohol Timeline Followback (TLFB) method.

4.b. Harmful use is drinking behavior that meets Diagnostic and Statistical Manual (DSM)-IV diagnostic criteria for an Alcohol Use Disorder (Alcohol Dependence or Alcohol Abuse).

  • Subjects must express a desire to reduce or stop alcohol use.
  • Female subjects must have a negative urine pregnancy test and must be either postmenopausal for at least 1 year or practicing an effective method of birth control (e.g., surgically sterile, spermicide with barrier, male partner sterilization; or absent and agrees to continue abstinence or to use an acceptable method of contraception, as listed above, should sexual activity commence).
  • Subjects must have a Breath Alcohol Concentration (BAC) of less than 0.02% when signing the informed consent form.

Exclusion Criteria

  • Psychotic disorders, bipolar disorders, dementia, or other psychiatric disorders judged to be unstable.
  • Subjects known to have clinically significant unstable medical conditions, including but not limited to: Clinically significant renal disease and/or impaired renal function as defined by clinically significant elevation of blood urea nitrogen (BUN) or creatinine or an estimated creatinine clearance of 5 times the upper limit of the normal range and/or a serum bilirubin > 2 times the upper limit of normal.
  • History of glaucoma.
  • History of kidney stones.
  • Concurrent participation in another alcohol treatment study or any study involving medications.
  • Female patients who are pregnant or lactating.
  • Topiramate use in the past week prior to study entry.
  • Use of medications for alcohol dependence (disulfiram, naltrexone, or acamprosate) within the past week.
  • Needing acute medical detoxification from alcohol based on a score of 12 or more on the Clinical Institute Withdrawal Assessment of Alcohol Scale (CIWA-AD).
  • Subjects who are legally mandated to participate in an alcohol treatment program.
  • Subjects who have had a suicide attempt in the past 6 months or suicidal ideation, with intent, in the 30 days prior to enrollment.
  • Subjects who have previously been treated with to
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01750268). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search